Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

@article{Keating2003RecombinantHB,
  title={Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.},
  author={Gillian M. Keating and Stuart Noble},
  journal={Drugs},
  year={2003},
  volume={63 10},
  pages={
          1021-51
        }
}
Engerix-B (Hep-B[Eng]) is a noninfectious recombinant DNA vaccine containing hepatitis B surface antigen (HBsAg). It is produced from genetically engineered yeast (Saccharomyces cerevisiae). Intramuscular Hep-B(Eng) [0-, 1-, 6-month schedule] has excellent immunogenicity in healthy neonates and infants, children, adolescents and adults, with seroprotection rates of 85-100% seen approximate, equals 1 month after the final dose of vaccine; seroprotection was defined as an antibody against HBsAg… CONTINUE READING
53 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

Similar Papers

Loading similar papers…